



2022 MX-A Intended Responses

ANTIBODY SPECIFICITIES by FLOW

	MX-01P		MX-02P	
	Class I Results	Class II Results	Class I Results	Class II Results
FLOW	B58, B57, A2, A32, B63, B49, B38, A25, B51, A23, B53, B27, B77, B59, Cw15, B37, B44, A24, Cw5, B52, Cw6, B47, Cw2, Cw18, Cw17, B46, B13, B72, B56, B62, Cw4, B50, B71, Cw12, A11, B35, B75	DR7, DR9, DQ9, DQ7, DQ8, DR52, DR12, DR4, DQB1-05, DQB1-06,	B45, B41, B50, B60, B49, B72, B13, B44, B76, B62, B61, B78, B71, B18, B35, B51, B47, B38, B75, B53, B39, B48, B77, B64, B59, B37, B52, B8, B65	Negative
	MX-03P		MX-04P	
	Class I Results	Class II Results	Class I Results	Class II Results
FLOW	Negative	Negative	Negative	Negative

CDC- complement-dependent cytotoxicity antibody specificities are no longer a reportable method due to inadequate group size.

CROSSMATCH RESULTS

MX-01P (1 st Set)		
Method	Against MX-05C	Against MX-06C
Direct Cytotoxicity	T and B - both POSITIVE	T and B - both POSITIVE
Flow	T and B - both POSITIVE	T and B - both POSITIVE
MX-02P (2 nd Set)		
Method	Against MX-05C	Against MX-06C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both POSITIVE	T and B - both POSITIVE
MX-03P (3 rd Set)		
Method	Against MX-05C	Against MX-06C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both NEGATIVE	T and B - both NEGATIVE
MX-04P (4 th Set)		
Method	Against MX-05C	Against MX-06C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both NEGATIVE	T and B - both NEGATIVE